FDA Approves TREMFYA® for Ulcerative Colitis Induction
- SSCTR Exco
- Sep 24
- 1 min read
Published via FDA & EU regulatory updates
The FDA has approved TREMFYA® as the first and only IL-23 inhibitor with both subcutaneous and IV options for induction and maintenance in UC and Crohn’s disease. Trial data showed higher remission and endoscopic improvement rates versus placebo, with benefits seen as early as Week 2.
👉 Read the full update: FDA approval of TREMFYA® for ulcerative colitis
Disclaimer
Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.
Comments